Repligen gets fast tracked for spinal muscular atrophy

Waltham, MA-based biotech Repligen has received FDA fast-track designation for its spinal muscular atrophy treatment, RG3039. The drug also received orphan drug status from the EMA. Repligen is preparing for its first Phase I trial of the drug. Repligen release

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.